Pancreatic stones of patients with chronic calcifying pancreatitis (CCP) hydrophobic interactions at pH 5.0 using a Phenyl-TSK column. This study showed with this assay that lithostathine concentrations (,ug/mg of total protein) were similar in CCP patients with alcoholic aetiology (mean (SD) 6.3 (2.7)) and other aetiologies (7.2 (3.7)), but one third of those estimated in patients without pancreatic disease (16.7 (4.3)). Similar concentrations were found, however, in chronic alcoholic patients without CCP (6.6 (3.3)) and in patients with CCP. It was concluded that decreased lithostathine concentration is associated with CCP, although such a decrease is not sufficient by itself for the disease to occur. (Gut 1995; 36: 630-636) 
that precipitates at neutral pH. That fragment is actually the Si form previously described as pancreatic stone protein in pancreatic stones. In vitro experiments have shown that lithostathine can inhibit CaCO3 nucleation and crystal growth.6 These findings led to the hypothesis that lithostathine participated in the control of stone formation in pancreatic ducts. In consequence patients with insufficient lithostathine concentration in juice were expected to be at risk for developing chronic calcifying pancreatitis (CCP). The finding that CCP patients had indeed reduced lithostathine mRNA concentration in pancreas supported that idea.7 Provansal-Cheylan et al 8 also showed that lithostathine concentration measured by enzyme linked immunosorbent assay (ELISA) was reduced in patients with CCP, compared with controls. It was, however, disturbing that similar studies performed with a radioimmunoassay8 or a fluorescent immunoassay9 were used instead of an ELISA failed to show any difference, although the monoclonal antibody used for antigen captation was the same in the three techniques.
Such discrepancies cast a doubt on the pathophysiological significance of decreased lithostathine expression in the pancreas and should therefore be explained. This was the aim of this study, in which we looked at possible differences in the affinity of the antibodies for the various forms of lithostathine and investigated the possible interference with the assay of uncontrolled activation of trypsinogen leading to transformation by trypsin of lithostathine into its insoluble derivative. In addition, a reliable non-immunological procedure for evaluation of lithostathine concentration in juice was developed and used in patients presenting with CCP or other pancreatic diseases, in alcoholic patients, and in controls. The The lithostathine fraction of a pancreatic juice was immunopurified as already described. It contained mostly the S2-5 forms and also a small amount of the S1 form. As already stated, all samples of pancreatic juice were routinely checked after collection for absence of uncontrolled trypsinogen activation. This was done by controlling the absence of detectable chymotrypsin activity because chymotrypsinogen is, among pancreatic zymogens, one of the most susceptible to activation by trypsin. Yet lithostathine S 1 was often present in samples devoid of detectable chymotrypsin activity, suggesting that the affinity of trypsin for lithostathine is much higher than for chymotrypsinogen, and that smaller j amounts of trypsin are sufficient for 20 lithostathine S2-5 cleavage. This is why we monitored lithostathine transformation by minimal amounts of trypsin. Trypsinogen concentration in juice is about 300 ,ug/ml. We used 0-13, 0 04, and 0. 013 ,ug/ml, corresponding respectively to 0.04, 0-01, and 0.004% of total potential trypsin activity in juice. With 0-13 ,ug/ml trypsin, lithostathine was already completely transformed after a two hour incubation. With 0-013 ,ug/ml, 25% of the lithostathine was transformed after 24 hours. It is noteworthy that under these experimental conditions, only lithostathine S1 was generated, showing that among possible trypsin cleavage sites in the molecule, the Arg 1l-Ile 12 bond is by far the most sensitive (Fig 2) . Experimental conditions were defined to permit separation of lithostathine from other proteins of pancreatic juice after fractionation iine fraction, on HPLC. To take advantage of the comparaithostathine tively high polarity of lithostathine, compared as measured with other pancreatic proteins, chromatond C, which graphic separation was based on hydrophobic S5 forms in interactions at pH 5 0, using a phenyl-TSK mmunoreac-column. In these conditions the elution profile protein) was of total pancreatic proteins showed several nd E, which peaks (Fig 3A) . SDS PAGE with correspondoreactivities. ing western blot analysis showed that all e S1 as well soluble S2-5 isoforms of lithostathine were n in small eluted as a single peak at 19.2 minutes, no the reliabil-other protein contaminant being detectable on y.
the gels (Fig 4) . When (Fig 3C) . In contrast, absence of significant amounts of other proteins under the lithostathine peak was checked as follows: a sample of juice was loaded onto the immunoaffinity column used for lithostathine purification. The flow through of the column on which lithostathine had been retained was analysed on the Phenyl-TSK column. All _-peaks were conserved apart from the lithostathine peak, which had disappeared (Fig 3B) . II1  II1  II1  II1  II1  II1  I'1   I I 1  I I 1   II1  II1  II1  II1  II1  II1   II1   II1  II1  II1  II1   30   0  5  10  15  20  25  30  35 Time (min) Figure 3 : HPLC separation ofpancreatic juice proteins. HPLC profiles obtained before (A) and after (B) immunoadsorption of lithostathine. The arrows show the peak remove( by the specific binding with the anti-lithostathine antibody. This peak was eluted at the same time as purified lithostathine S2-5. ((C) solid line, S2-5 isoforms; broken line, Sl isoform.) sample of purified lithostathine and measurir the absorbance of the peaks. Reliability of tl quantification was controlled by running c the column aliquots of the same juice, to whi( were added increasing amounts of purific lithostathine (Table) . Recovery (about 900/ was satisfactory. from the five groups of patients. Peaks corresponding to secretory proteins, including lithostathine appear at the same times but their comparative areas vary widely. Figures 6 and 7 show the amounts of lithostathine, estimated as already described. The nine non-alcoholic patients without pancreatic disease (control group) had a lithostathine concentration mean (SD) of 16-7 (4.3) ,ig/mg of total proteins. Similar values were obtained in patients with pancreatic diseases other than CCP (20-5 j (7.5)). By contrast, alcoholic CCP, non-40 alcoholic CCP, and alcoholic patients showed significantly lower values (6.7 (3.9), 7.2 (3.7), and 6-6 (3.3) ,ug/mg of total proteins respectively; p<0 001). When lithostathine concentrations were estimated in pg/ml similar results were obtained: lithostathine concentrations in alcoholic CCP (10-7 (2.8)), non-alcoholic CCP (10.5 (3-1)), and alcoholic patients (182 (10.1)) were significantly lower than in patients with other pancreatic diseases (35 (9)) and controls (40 (23) (1 9 (0.9)) alcoholic patients (2.9 (1.2)), pancreatic diseases other than CCP (2.5 (0.8)), controls (2.8 (1.4) ). (Fig 6) The group of patients with chronic alcoholism and no pancreatic disease, however, showed the same decrease in relative synthesis of lithostathine as patients with CCP, suggesting that, in patients, low lithostathine synthesis might be associated with alcoholism and not with the disease in itself. To clarify that point we identified among CCP patients a group of six cases with causes other than alcoholism and saw that their comparative rate of lithostathine synthesis was also lowered, similar to patients with chronic alcoholic pancreatitis. It was concluded that decreased lithostathine synthesis is associated with CCP, whatever the aetiology, and that such a decrease is not sufficient to evoke the disease, as decreased lithostathine is found in chronic alcoholic patients without pancreatic disease. Lithostathine amounts in juice could also be used to calculate actual concentrations of the protein (,ug/ml, Fig 7) . Those values reflect the inhibitory activity of the protein in juice. As such, they are of interest to investigate a possible relation between decreased lithostathine activity and occurrence of the disease. As Fig 7 shows , lithostathine concentration was decreased in all patients with CCP. Concentration was also decreased in alcoholic patients without pancreatic disease. Results in that group and in CCP patients were not statistically different, but suggested that lithostathine concentrations might be lower in CCP patients. We therefore conclude that lithostathine activity in juice is lower in CCP patients than in controls and that decrease is not sufficient to account for the disorder as alcoholic patients without pancreatic disease also show decreased lithostathine concentration.
Expressing lithostathine as relative amounts to total protein or as concentration led to similar conclusions. It should be borne in mind, however, that the volumes of juice samples collected by ERCP, which are used to calculate lithostathine concentrations, vary considerably during exogenous stimulation. In our protocol, sample collection was standardised to reduce to a minimum the dispersion of the results. Such standardisation might be difficult to achieve in general practice. When lithostathine quantification is requested in a patient under investigation for CCP, it is therefore advisable to calculate the comparative amount of lithostathine to total secretory protein (as in Fig 6) , which is independent of the sample collected and provides the same information as the actual concentration.
HPLC quantification of lithostathine in pancreatic juice is reliable but time consuming compared with an immunoassay. It is well adapted to experimental studies but efforts should be made to make available a reliable assay, simple and cheap enough for routine clinical use.
